Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANGANY’s First Clinical Trial Concludes on Time and with Positive Results
Details : ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for the treatment of cat allergy. It is being evaluated in phase 1 clinical trials for the same.
Product Name : ANG-101
Product Type : Vaccine
Upfront Cash : Inapplicable
January 29, 2024
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for the treatment of cat allergy. It is being evaluated in phase 1 clinical trials for the same.
Product Name : ANG-101
Product Type : Vaccine
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable